MicroRNA Mimics Based on the miR-15/107 Consensus Sequence Sensitise NSCLC Cells to Targeted Therapy
International Journal of Molecular Sciences · 16.03.2026 · 27 (6) · 2701
DOI: 10.3390/ijms27062701 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 16.03.2026. Verfasst von Carien Carpenter und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Molecular Medicine, University of Otago, Dunedin 9054, New Zealand. Hauptthemen laut MEDLINE: MicroRNAs, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, ErbB Receptors. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Otago Innovation Limited, Royal Society of New Zealand Marsden Fund, University of Otago Master’s writing bursary.
Abstract (Originalsprache)
Non-small cell lung cancer (NSCLC) is the leading cause of lung cancer deaths, with resistance to targeted therapies posing a major clinical challenge. Drug-tolerant persister (DTP) cells are key contributors to resistance, and targeting them offers new strategies to enhance existing treatments. MicroRNAs (miRNAs), particularly the tumour-suppressive miR-15/107 family, offer promise due to their ability to target multiple oncogenic pathways. This study evaluated a synthetic consensus miRNA mimic, conmiR-15/107, in NSCLC cell line models. Dose–response assays showed robust, dose-dependent growth inhibition in both EGFR-mutant (PC9) and KRAS-mutant (H358 and A549) lung adenocarcinoma cells, but not in the human bronchial epithelial cell line BEAS-2B. When combined with EGFR inhibitors (osimertinib and gefitinib) in PC9 cells, the mimics showed a higher rate of growth inhibition compared with the controls and reduced IC50 values. Similarly, conmiR-15/107 enhanced growth inhibition by the KRAS inhibitors sotorasib and adagrasib in H358 cells. RT-qPCR confirmed downregulation of conmiR-15/107 targets, including MEK1, BCL2 and BRCA1, suggesting a multi-target mechanism of action. Long-term assays showed that the mimics reduced the survival and delayed the proliferation of DTPs in osimertinib-treated PC9 cells as well as sotorasib-treated H358 cells. These findings support conmiR-15/107 as a potential adjunct to targeted therapy, capable of enhancing treatment efficacy and delaying resistance in lung adenocarcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Molecular Medicine, University of Otago, Dunedin 9054, New Zealand.
- Maurice Wilkins Centre for Molecular Biodiscovery, The University of Auckland, Auckland 1142, New Zealand.
- Sydney Local Health District, Sydney, NSW 2065, Australia.
- Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2050, Australia.
ORCID-Profile: Nico van Zandwijk, Glen Reid
Förderung
- Otago Innovation Limited
- Royal Society of New Zealand Marsden Fund
- University of Otago Master’s writing bursary
- University of Otago Masters scholarship
- PhD scholarship from the Cancer Research Trust of New Zealand
Zitieren
APA
Carpenter, C., Simmons, N., Davis, W. J. H., Thompson, M., Zandwijk, N. V., Drummond, C. J., & Reid, G. (2026). MicroRNA Mimics Based on the miR-15/107 Consensus Sequence Sensitise NSCLC Cells to Targeted Therapy. International Journal of Molecular Sciences, 27(6), 2701. https://doi.org/10.3390/ijms27062701
Vancouver
Carpenter C, Simmons N, Davis WJH, Thompson M, Zandwijk NV, Drummond CJ, et al. MicroRNA Mimics Based on the miR-15/107 Consensus Sequence Sensitise NSCLC Cells to Targeted Therapy. International Journal of Molecular Sciences. 2026;27(6):2701. doi:10.3390/ijms27062701
BibTeX
@article{Carpenter2026,
author = {Carpenter, Carien and Simmons, Nina and Davis, William J H and Thompson, Madeleine and Zandwijk, Nico van and Drummond, Catherine J and Reid, Glen},
title = {MicroRNA Mimics Based on the miR-15/107 Consensus Sequence Sensitise NSCLC Cells to Targeted Therapy},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {6},
pages = {2701},
doi = {10.3390/ijms27062701}
}
EUVIMED